B+
Bull case
25%
Probability
Target price
$52.00
+68.2% vs current
IMVT
ImmunovantANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$37.00
+19.7% vs current
B-
Bear case
25%
Probability
Target price
$18.00
-41.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-23
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+65.5
Score
AI commentary
The post-earnings reaction was driven more by IMVT-1402 rheumatoid-arthritis data than by the wider fiscal Q4 loss; coverage cited an 8.41% pre-market gain and framed the earnings miss as secondary. Analyst follow-through was only partial, with Stifel reportedly reiterating Buy/$49, while broader revision coverage was still sparse. This remains a monitoring-style biopharma name rather than a clean post-print rerate because the main value driver is still a program-specific clinical readout path, not operating leverage.
RankAlpha Sentiment Codex - 2026-05-23
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20eventQ4/FY26 earnings release was overshadowed by IMVT-1402 RA dataHigh impact
On May 20, 2026, Immunovant reported a fiscal fourth-quarter net loss of $147.9 million ($0.73/share) and FY26 net loss of $505.6 million ($2.77/share), but the release also highlighted IMVT-1402 Week 16 D2T RA ACR20/50/70 response rates of 72.7%/54.5%/35.8%, no new drug-related safety signals, and $902.1 million in cash; batoclimab was discontinued and management said other clinical timelines remain on track [#8-K-2026-05-20].
2026-10-31catalystIMVT-1402 D2T RA and CLE updates in 2H 2026 remain the next re-rating testHigh impact
Management said the D2T RA study remains ongoing, with further updates and topline data from the fully enrolled CLE proof-of-concept trial expected in 2H 2026; this is the next meaningful readout set that can confirm whether the open-label RA signal translates beyond the initial period [#8-K-2026-05-20].
2027-06-30catalystGraves' disease and other potentially registrational programs are the longer-dated valuation driverHigh impact
The company said other clinical development timelines remain on track for IMVT-1402, including potentially registrational trials in Graves' disease, myasthenia gravis, CIDP and SjD; coupled with the stated runway through potential commercial launch in GD, these programs are the main medium-term valuation support [#8-K-2026-05-20].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-23 • Updated nightlySource: Internal modelMethodology